Incobotulinumtoxin A for Sialorrhea in Neurological Disorders: A Real-Life Experience

被引：13

作者：

Martinez-Poles, Javier ^{[1
]}

Nedkova-Hristova, Velina ^{[1
]}

Bernardo Escribano-Paredes, Jose ^{[1
]}

Garcia-Madrona, Sebastian ^{[1
]}

Natera-Villalba, Elena ^{[1
]}

Estevez-Fraga, Carlos ^{[1
,2
]}

Lopez-Sendon Moreno, Jose Luis ^{[1
]}

Aviles-Olmos, Iciar ^{[1
]}

Sanchez Diaz, Gema ^{[1
]}

Martinez Castrillo, Juan Carlos ^{[1
]}

Alonso-Canovas, Araceli ^{[1
]}

机构：

[1] Hosp Univ Ramon y Cajal, Dept Neurol, Madrid 28034, Spain

[2] UCL Inst Neurol, Dept Neurodegenerat Dis, London WC1N 3RX, England

来源：

TOXINS | 2018年 / 10卷 / 06期

关键词：

sialorrhea; neurological disorders; Parkinson's disease; botulinum toxin type A; incobotulinumtoxin A; TOXIN TYPE-A; RANDOMIZED CONTROLLED-TRIAL; PARKINSONS-DISEASE; DOUBLE-BLIND; COMPLEXING PROTEINS; BOTULINUM TOXINS; EFFICACY; SAFETY; METAANALYSIS; INJECTION;

D O I：

10.3390/toxins10060217

中图分类号：

TS2 [食品工业];

学科分类号：

0832 ;

摘要：

Botulinum toxin type A is one of the most useful treatments of sialorrhea in neurological disorders. Evidence for the use of incobotulinumtoxin A (inco-A) in the treatment of sialorrhea is limited. Thirty-six patients with sialorrhea were treated with infiltrations of inco-A into both parotid glands. The severity of sialorrhea was evaluated by the Drooling Severity Scale (DSS), and the Drooling Frequency Scale (DFS). Patients' perceptions of clinical benefit were recorded via the Patient Global Impression of Improvement (PGI-I) scale. Following treatment, there was a significant difference in both the DFS and the DSS (p < 0.001). Clinical benefits on the basis of the PGI-I were present in up to 90% of patients.

引用

页数：8

共 50 条

[41] Prosigna test in breast cancer: real-life experience
Hequet, D.
Harrissart, G.
Krief, D.
Maumy, L.
Lerebours, F.
Menet, E.
Callens, C.
Rouzier, R.
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2021, 188 (01) : 141 - 147
[42] Indwelling pleural catheters: an overview and real-life experience
Messeder, S. J.
Thomson, M. C.
Hu, M. K.
Chetty, M.
Currie, G. P.
[J]. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2019, 112 (08) : 599 - 604
[43] Epidemiology and real-life experience in progressive pulmonary fibrosis
Valenzuela, Claudia
Cottin, Vincent
[J]. CURRENT OPINION IN PULMONARY MEDICINE, 2022, 28 (05) : 407 - 413
[44] Predictors of vedolizumab response to induction: Real-life experience
Gutierrez, A.
Sempere, L.
Belvis, M.
Vazquez, J. M.
Laveda, R.
Garcia, M.
Arguelles-Arias, F.
Pallares, H.
Castro, L.
Gomez, E.
Maldonado, B.
[J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S297 - S297
[45] PIRFENIDONE IN CHRONIC HYPERSENSITIVITY PNEUMONITIS: A REAL-LIFE EXPERIENCE
Shibata, Sho
Furusawa, Haruhiko
Inase, Naohiko
[J]. SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2018, 35 (02) : 139 - 142
[46] Clinical experience on intravitreal ranibizumab for DME on a real-life
Airaghi, Giulia
Donati, Simone
Caprani, Simona Maria
Gandolfi, Carlo
Premoli, Laura
Battistini, Serena
Chiaravalli, Maurizio
Azzolini, Claudio
[J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
[47] Real-life experience of anifrolumab for cutaneous lupus erythematous
Viedma-Martinez, Myriam
Garrido-Gamarro, Blanca
Villegas-Romero, Isabel
Millan-Cayetano, Francisco Jose
Jimenez-Gallo, David
Linares-Barrios, Mario
[J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023,
[48] Transcatheter aortic valve implantation: a real-life experience
Marta Braga, M.
Araujo, P.
Nunes, A.
Torres, S.
Pinto, R.
Rodrigues, J.
Rodrigues, R. A.
Almeida, P. B.
Vasconcelos, M.
Magalhaes, D.
Silva, J. C.
Maciel, M. J.
[J]. EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 131 - 131
[49] Reporting real-life experience with drugs in lymphoma patients
Argnani, Lisa
Zinzani, Pier Luigi
[J]. HEMATOLOGICAL ONCOLOGY, 2017, 35 (04) : 909 - 910
[50] EPIDEMIOLOGY OF DRUG-ABUSE AND REAL-LIFE EXPERIENCE
FACY, F
[J]. ANNALES DE MEDECINE INTERNE, 1994, 145 : 7 - 8

← 1 2 3 4 5 →